# Second Line Breast Cancer Trial

> **NCT00635713** · PHASE3 · COMPLETED · sponsor: **AstraZeneca** · enrollment: 588 (estimated)

## Conditions studied

- Advanced Breast Cancer

## Interventions

- **DRUG:** Fulvestrant
- **DRUG:** Anastrozole
- **DRUG:** Fulvestrant

## Key facts

- **NCT ID:** NCT00635713
- **Lead sponsor:** AstraZeneca
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 1997-05
- **Primary completion:** —
- **Final completion:** 2004-09
- **Target enrollment:** 588 (ESTIMATED)
- **Last updated:** 2009-04-10


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00635713

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00635713, "Second Line Breast Cancer Trial". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT00635713. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*